PolyPeptide Laboratories. PolyPeptide Laboratories (Torrance, CA) is building a new peptide plant in Ambernath, India, which is scheduled to be operational in 2008. Last year,
it increased its peptide manufacturing capacity in Torrance, California; Malmo, Sweden; and Hillerod, Denmark. These expansions
increased solid-phase peptide synthesis capacity, complementing its large-scale, solution-phase synthesis capabilities in
Malmo and Hillerod. The company also expanded its preGMP development capabilities in the United States.
NeoMPS (Strasbourg, France) is planning to invest EUR10 million ($13.6 million) to expand peptide capacity at its facility in Strasbourg,
France, with completion scheduled for mid-2008. The investment more than triples the company's large-scale manufacturing capacities
(solid and liquid phases) in Strasbourg. The company has multi kilogram-scale CGMP peptide capacity at its facilities in Strasbourg
and San Diego.
Bachem (Bubendorf, Switzerland) invested $10 million to expand production capacity by 40% for the CGMP manufacture of peptide active
ingredients at its facilities in Torrance, California. The company added a new production unit for solid-phase peptide synthesis
and purification that become operational in July 2006.
Last year Almac Sciences (Craigavon, Northern Ireland) commissioned a £500,000 ($993,000) package of new assets at its facilities in Northern Ireland
and Scotland. New investment at its large-scale, multi-product site at Craigavon, Northern Ireland included automated peptide
synthesis equipment, a freeze-drying suite, and preparative high-performance liquid chromatography. New equipment for small-scale
peptide synthesis was added to its production and research and development center in Edinburgh. Almac specializes in long-chain
peptides and has developed synthesis and purification techniques to make peptides up to 170 amino acids in length.
In 2006, Lonza acquired UCB Bioproducts and its peptide manufacturing facility in Braine-l'Alleud, Belgium and completed its integration into Lonza in December
2006. The facility has manufactured over 400 preclinical and clinical peptide drug candidates, estimates Lonza. Examples of
generic peptide APIs manufactured at the Braine facility include somatostatin and desmopressin.
Genzyme Pharmaceuticals (Cambridge, MA), a contract peptide manufacturer, is partnered with Brookwood Pharmaceuticals, Inc. (Birmingham, Alabama) to offer customized solutions for parenteral formulations by combining expertise in peptide delivery
and synthesis. The companies formed a pact last year.
1. J. Lakshmikanthan, "Outsouricng: Biologics: The CMO Advantage," BioPharm Intl. 20 (2) 40–48 (2007).